Related Experiment Video

Updated: Jun 3, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Brivanib alaninate for cancer

Ivan Diaz-Padilla1, Lillian L Siu

  • 1Princess Margaret Hospital, Toronto, Ontario, M5G2M9 Canada. lillian.siu@uhn.on.ca

Expert Opinion on Investigational Drugs
|March 12, 2011
PubMed
Abstract

Insights

Brivanib, a dual tyrosine kinase inhibitor, shows tolerable safety and promising efficacy in treating hepatocellular carcinoma and colorectal cancer. Further studies are ongoing to evaluate its potential in other solid tumors and combinations.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Angiogenesis inhibition is a key strategy for solid tumor treatment.
  • Brivanib is a dual tyrosine kinase inhibitor targeting VEGFR-2 and FGFR.

Purpose of the Study:

  • To review preclinical and clinical data of brivanib in cancer treatment.
  • To summarize brivanib's safety, efficacy, and pharmacokinetic/pharmacodynamic profiles.

Main Methods:

  • Literature review of published data up to December 2010.
  • Analysis of preclinical and clinical trial results presented in abstracts and journals.

Main Results:

  • Brivanib demonstrates a tolerable safety profile and favorable pharmacokinetics.
  • Evidence of target inhibition in surrogate tissues supports brivanib's mechanism.
  • Oral administration of 800 mg once daily is supported by clinical data.

Conclusions:

  • Brivanib shows promise as a single agent in hepatocellular carcinoma.
  • Combination therapy with cetuximab demonstrates activity in colorectal cancer.
  • Ongoing trials are exploring brivanib with chemotherapy and in other solid tumors.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring08:45

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...